Evidence for a Null Effect of L-10BPA Neutron Capture Therapy on Mouse Brain Dopamine Tracts

  • Barry J. Allen
  • Yohanes Setiawan
  • Douglas E. Moore
  • Glenda Halliday
  • Tony Harding

Abstract

The amino acid melanin precursor analogue, p-boronophenylalanine (BPA) has previously been tested in melanoma bearing animals1,2 and used in clinical trials of BNCT.3,4 In the case of melanoma, it is a rational biochemical approach to load the tumour with this precursor analogue, since melanin is synthesised from the amino acid phenylalanine. However, it has been found that BPA can selectively accumulate in tumours other than melanoma; for example, in a murine mammary adenocarcinoma, in a rat glioma, and in a xenografted human glioma.4 The use of BPA has therefore been proposed for BNCT of high grade brain cancer, since it can penetrate the blood brain barrier (BBB), so that it is possible to load the required concentration of boron into the tumour cells. Pharmacokinetic studies of BPA-fructose have been performed in human patients with melanoma or glioma and uptake into cerebral tumours was found to be adequate for BNCT.5,6

Keywords

Tyrosine Hydroxylase Neutron Radiation Neutron Capture Boron Neutron Capture Therapy Olfactory Tubercle 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    B.J. Allen, S. Corderoy-Buck, J.L. Mallcsch, K. Crotty, and D.L. Moore, Local control of subcutaneous murine melanoma xenografts in nude mice by neutron capture therapy. Melanoma Res.. 2: 253–2, 1992.Google Scholar
  2. 2.
    J.A. Coderre, J.D. Glass, R.G. Fairchild, U. Roy, S. Cohen, and I. Fand, Selective targeting of boronophenylalanine to melanoma in BALBíc mice for neutron capture therapy. Cancer Res., 47: 6377–6383, 1987.PubMedGoogle Scholar
  3. 3.
    Y. Mishima, C. Honda, M. Ichihashi, I I. Obara, J. Hiratsuka, H. Fukuda, T. Karashima, T. Kobayashi, K. Kanda, and K. Yoshino, Treatment of maligant melanoma by single thermal neutron capture therapy with melanoma seeking 1°B-compound. Lancet, 1989, 0: 388–389.CrossRefGoogle Scholar
  4. 4.
    J.A. Coderre, J.D. Glass, R.G. Fairchild, P.L. Micca, I. Fand, and D.D. Joel. Selective delivery of boron by the melanin precursor analogue p-boronphenylalanine to tumors other than melanoma. Cancer Res.. 50: 138–141, 1990.Google Scholar
  5. 5.
    J.L. Mallesch, D.E. Moore, B.J. Allen, W.H. McCarthy, R. Jones. and W.A. Stening, The pharmacokinetics of p-boronophenylalanine. fructose in human patients with glioma and metastatic melanoma, Int..1. Radiation Oncology Biol. Phys., 28: 1055–1056, 1994.CrossRefGoogle Scholar
  6. 6.
    J.A. Coderre, A phase-1 biodistribution study of p-boronophenylalanine. in “Boron Neutron Capture Therapy,” D. Gabel and R. Moss, eds., Plenum Press, New York. 1992, pp. 564–465.Google Scholar
  7. 7.
    J.R. Cooper, F.E. Bloom, and R.H. Roth, “The Biochemical Basis of Neuropharmacology.” 6th ed.. Oxford University Press, Oxford, 1991 pp. 1–35.Google Scholar
  8. 8.
    S.R. Tamat, D.E. Moore, and B.J. Allen, Assay of boron in biological tissues by inductively coupled plasma atomic emission spectrometry, Anal. Cheri., 59: 2161–2164, 1987.CrossRefGoogle Scholar
  9. 9.
    H.A. Meriaty, and B.J. Allen, Optimisation of neutron capture radiography for analysis of boron in tissues. in: A.H. Soloway, R.F. Barth, and D.E. Carpenter, eds., “Advances in Neutron Capture Therapy,” Plenum Press, New York, 1993, pp. 445–448.Google Scholar
  10. 10.
    S.M. Hsu, L. Raine, and H. Fanger, Use of avidin-biotin-peroxidase conplex (ABC) in inmmunoperoxidase techniques: a comparison between ABC and unlabelled antibody (PAP) procedures, J. Hi.stochem. Cytochem., 29: 577–580, 1981.CrossRefGoogle Scholar
  11. 11.
    W.A. Hunt, T.K. Dalton, and J.H. Darden, Transient alterations in neurotransmitter activity in the caudate nucleus of rat brain after a high dose of ionizing radiation. Radiation Res., 80: 556–562, 1979.PubMedCrossRefGoogle Scholar
  12. 12.
    W.A. Hunt, T.K. Dalton, J.A. Joseph, and B.M. Rabin, Reduction of 3-methoxytyramineconcentrations in the caudate nucleus of rats after exposure to high-energy iron particles: evidence for deficits in dopaminergic neurons, Radiation Res., 21: 169–174, 1990.CrossRefGoogle Scholar
  13. 13.
    I. Ferrer, T. Serrano, R. Rivera, M. Olive, M.J. Zujar, and F. Graus, Radiosensitive populations and recovery in X-ray-induced apoptosis in the developing cerebellum, Acta Neuropathologica, 86: 491–500, 1993.PubMedGoogle Scholar
  14. 14.
    H. Tauchi and S. Sawada, Analysis of mitotic cell death caused by radiation in mouse leukaemia L5178Y cells: apoptosis is the ultimate form of cell death following mitotic failure. Int. J Radiation Biol., 65: 449–55, 1994.CrossRefGoogle Scholar
  15. 15.
    G.W. Casarett, Radiation histopathology, Florida: CRC Press Inc., 1980, pp. 29–38.Google Scholar
  16. 16.
    J.W. Hopewell, Late radiation damage to the central nervous system: a radiobiological interpretation, Neuropath. Appl. Neurobiology, 5: 329–343, 1979.Google Scholar
  17. 17.
    J.M. Mallesch, D.E. Moore, M.G. Carolan, K. Narayan, and B.J. Allen, Response of normal and tumor vasculature to boron neutron capture therapy. (These Proceedings) Google Scholar
  18. 18.
    G.M. Morris, G. Constantine, G. Ross, T.K. Yeung, and J.W. Hopewell, Boron neutron capture therapy: long-term effects on the skin and spinal cord of the rat. Radiation Res., 135: 380–386, 1993.PubMedCrossRefGoogle Scholar
  19. 19.
    K.Z. Matalka, R.F. Barth, M.Q. Bailey, D.A. Wilkie, A. Koestner, and J.W. Hopewell, Radiation effects of boron neutron capture therapy on brain, skin, and eye of rats, Int. J. Radiation Oncology Biol. Phys., 28: 1089–1097, 1994.CrossRefGoogle Scholar
  20. 20.
    V.M. Pickel, T.H. Joh, P.M. Field, C.G. Becker, and D.J. Reis, Cellular localisation of tyrosine hydroxylase by immunohistochemistry, J. Histochem. Cvtochem., 23: 1–12, 1975.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1996

Authors and Affiliations

  • Barry J. Allen
    • 1
    • 2
  • Yohanes Setiawan
    • 2
  • Douglas E. Moore
    • 2
  • Glenda Halliday
    • 2
  • Tony Harding
    • 2
  1. 1.St George Cancer Care CentreKogarahAustralia
  2. 2.Departments of Pharmacy and PathologyUniversity of SydneyAustralia

Personalised recommendations